Biomarker & Intervention Discovery
Restless Legs Syndrome (RLS)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
Spontaneous remissionPrimary RLS is chronic; spontaneous remission in mild cases ~30-40% over 5 years; pregnancy-induced RLS remits…
Best-intervention remissionIron IV supplementation in iron-deficient RLS: 57% responders vs 35% placebo (ferric carboxymaltose — Phase 3…
Gap sizeModerate — iron deficiency treatment is underused as primary intervention; dopamine agonists chronically overused…
Primary barrierframing/practice
Full remission profile →
Remission & chronicity
Spontaneous remission
Primary RLS is chronic; spontaneous remission in mild cases ~30-40% over 5 years; pregnancy-induced RLS remits post-delivery; augmentation on dopaminergic drugs worsens symptoms in 60-80% at 10 years
Best-intervention remission
Iron IV supplementation in iron-deficient RLS: 57% responders vs 35% placebo (ferric carboxymaltose — Phase 3 positive); alpha-2-delta ligands (gabapentin enacarbil, pregabalin): 53-55% RLS responders; dopamine agonists (pramipexole, ropinirole): 70-80% initial response but augmentation in 60-80% at 10 years
Gap size
Moderate — iron deficiency treatment is underused as primary intervention; dopamine agonists chronically overused despite augmentation risk
Primary barrier
framing/practice
IV iron therapy for iron-deficient RLS (<50 µg/L ferritin) is highly effective and underused; dopamine agonists are first-line in most practices despite augmentation being essentially inevitable in long-term use; augmentation causes 24-hour symptoms worse than original disease
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Restless Legs Syndrome (RLS)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."